Literature DB >> 26883702

Successful Therapy of Murine Visceral Leishmaniasis with Astrakurkurone, a Triterpene Isolated from the Mushroom Astraeus hygrometricus, Involves the Induction of Protective Cell-Mediated Immunity and TLR9.

Suvadip Mallick1, Aritri Dutta1, Ankur Chaudhuri2, Debasri Mukherjee3, Somaditya Dey1, Subhadra Halder4, Joydip Ghosh1, Debarati Mukherjee1, Sirin Salma Sultana1, Gunjan Biswas5, Tapan Kumar Lai5, Pradyumna Patra6, Indranil Sarkar7, Sibani Chakraborty2, Bhaskar Saha3, Krishnendu Acharya5, Chiranjib Pal8.   

Abstract

In our previous report, we showed that astrakurkurone, a triterpene isolated from the Indian mushroom Astraeus hygrometricus (Pers.) Morgan, induced reactive oxygen species, leading to apoptosis in Leishmania donovani promastigotes, and also was effective in inhibiting intracellular amastigotes at the 50% inhibitory concentration of 2.5 μg/ml. The aim of the present study is to characterize the associated immunomodulatory potentials and cellular activation provided by astrakurkurone, leading to effective antileishmanial activity in vitro and in vivo Astrakurkurone-mediated antileishmanial activity was evaluated by real-time PCR and flow cytometry. The involvement of Toll-like receptor 9 (TLR9) was studied by in vitro assay in the presence of a TLR9 agonist and antagonist and by in silico modeling of a three-dimensional structure of the ectodomain of TLR9 and its interaction with astrakurkurone. Astrakurkurone caused a significant increase in TLR9 expression of L. donovani-infected macrophages along with the activation of proinflammatory responses. The involvement of TLR9 in astrakurkurone-mediated amastigote killing has been evidenced from the fact that a TLR9 agonist (CpG, ODN 1826) in combination with astrakurkurone enhanced the amastigote killing, while a TLR9 antagonist (bafilomycin A1) alone or in combination with astrakurkurone curbed the amastigote killing, which could be further justified by in silico evidence of docking between mouse TLR9 and astrakurkurone. Astrakurkurone was found to reduce the parasite burden in vivo by inducing protective cytokines, gamma interferon and interleukin 17. Moreover, astrakurkurone was nontoxic toward peripheral blood mononuclear cells of immunocompromised patients with visceral leishmaniasis. Astrakurkurone, a nontoxic antileishmanial, enhances the immune efficiency of host cells, leading to parasite clearance in vitro and in vivo.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26883702      PMCID: PMC4862535          DOI: 10.1128/AAC.01943-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.

Authors:  Neeta Datta; Snigdha Mukherjee; Lopamudra Das; Pijush K Das
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

2.  CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.

Authors:  Suman Gupta; Shraddha A Sane; Nishi Shakya; Preeti Vishwakarma; W Haq
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

3.  Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species.

Authors:  Diogo G Valadares; Mariana C Duarte; Jamil S Oliveira; Miguel A Chávez-Fumagalli; Vivian T Martins; Lourena E Costa; João Paulo V Leite; Marcelo M Santoro; Wiliam C B Régis; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasitol Int       Date:  2011-06-24       Impact factor: 2.230

4.  Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection.

Authors:  H S Chandel; S P Pandey; D Shukla; K Lalsare; S K Selvaraj; M K Jha; B Saha
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

5.  Leishmanicidal and anticandidal activity of constituents of Indian edible mushroom Astraeus hygrometricus.

Authors:  Tapan K Lai; Gunjan Biswas; Soumya Chatterjee; Aritri Dutta; Chiranjib Pal; Julie Banerji; Nattamai Bhuvanesh; Joseph H Reibenspies; Krishnendu Acharya
Journal:  Chem Biodivers       Date:  2012-08       Impact factor: 2.408

6.  Induction of macrophage killing of Leishmania donovani by human CD4+ T cell clones.

Authors:  P C Melby; G Valencia-Pacheco; F Andrade-Narváez
Journal:  Arch Med Res       Date:  1996       Impact factor: 2.235

7.  In vitro activity of hypnophilin from Lentinus strigosus: a potential prototype for Chagas disease and leishmaniasis chemotherapy.

Authors:  E M Souza-Fagundes; B B Cota; L H Rosa; A J Romanha; R Corrêa-Oliveira; C A Rosa; C L Zani; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Braz J Med Biol Res       Date:  2010-10-14       Impact factor: 2.590

8.  Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism.

Authors:  Dinesh Chandra; Sita Naik
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

9.  Toll-like receptors in leishmania infections: guardians or promoters?

Authors:  Marilia S Faria; Flavia C G Reis; Ana Paula C A Lima
Journal:  J Parasitol Res       Date:  2012-03-15

10.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  6 in total

1.  Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model.

Authors:  Antara Banerjee; Parna Bhattacharya; Pradeep K Dagur; Subir Karmakar; Nevien Ismail; Amritanshu B Joshi; Adovi D Akue; Mark KuKuruga; John Philip McCoy; Ranadhir Dey; Hira L Nakhasi
Journal:  J Immunol       Date:  2017-11-29       Impact factor: 5.422

2.  Combination of Mycobacterium indicus pranii and Heat-Induced Promastigotes Cures Drug-Resistant Leishmania Infection: Critical Role of Interleukin-6-Producing Classical Dendritic Cells.

Authors:  Somaditya Dey; Debarati Mukherjee; Sirin Salma Sultana; Suvadip Mallick; Aritri Dutta; Joydip Ghosh; Aabid Hussain; Biswajyoti Sarkar; Supratim Mandal; Pradyumna Patra; Bhaskar Saha; Chiranjib Pal
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

Review 3.  Mushrooms: an emerging resource for therapeutic terpenoids.

Authors:  Adhiraj Dasgupta; Krishnendu Acharya
Journal:  3 Biotech       Date:  2019-09-24       Impact factor: 2.406

4.  Therapeutic effect of ursolic acid in experimental visceral leishmaniasis.

Authors:  Jéssica A Jesus; Thais N Fragoso; Eduardo S Yamamoto; Márcia D Laurenti; Marcelo S Silva; Aurea F Ferreira; João Henrique G Lago; Gabriela Santos-Gomes; Luiz Felipe D Passero
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-12-08       Impact factor: 4.077

Review 5.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 6.  Role of Cytokines in Experimental and Human Visceral Leishmaniasis.

Authors:  Mukesh Samant; Utkarsha Sahu; Satish Chandra Pandey; Prashant Khare
Journal:  Front Cell Infect Microbiol       Date:  2021-02-18       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.